LEADER 01591nam 2200385 450 001 9910583341503321 005 20230120003550.0 010 $a0-12-809445-1 010 $a0-12-809400-1 035 $a(CKB)4330000000079374 035 $a(MiAaPQ)EBC4856918 035 $a(EXLCZ)994330000000079374 100 $a20170530h20172017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aAdverse events and oncotargeted kinase inhibitors /$fGiuseppe Tridente 210 1$aLondon, England :$cAcademic Press,$d2017. 210 4$dİ2017 215 $a1 online resource (717 pages) $cillustrations, tables 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aIntroduction -- Kinases -- Kinase inhibitors -- Adverse events -- Imantinib -- Gefitinib -- Erlotinib -- Sorafenib -- Sunitinib -- Dasatinib -- Lapatinib -- Nilotinib -- Pazopanib -- Vandetanib -- Vemurafenib -- Crizotinib -- Ruxolitinib -- Axitinib -- Bosutinib -- Regorafenib -- Cabozantinib -- Ponatinib -- Dabrafenib -- Trametinib -- Afatinib -- Idelaisib -- Ibrutinib -- Overview -- Conclusion and perspectives. 606 $aProtein-tyrosine kinase$xInhibitors 615 0$aProtein-tyrosine kinase$xInhibitors. 676 $a612.01516 700 $aTridente$b G.$0101335 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910583341503321 996 $aAdverse events and oncotargeted kinase inhibitors$91916110 997 $aUNINA